Guardant Health, INC Form 4 insider transactions

Guardant Health's CFO, Michael Brian Bell, increased his direct beneficial ownership of common stock through RSU vestings and a tax-related disposition.

Guardant Health Co-CEO AmirAli Talasaz reported the vesting of restricted stock units and subsequent tax-related share dispositions.

Guardant Health Director Steve Krognes converted 154 restricted stock units into common stock on September 30, 2025, increasing his direct common stock holdings.

Guardant Health Co-CEO Helmy Eltoukhy reported recent acquisitions of common stock through RSU vesting and subsequent tax-related dispositions.

Guardant Health Director Alex M. Azar II was granted stock options and restricted stock units totaling 17,136 shares, vesting over four years.

Guardant Health Director Manuel Hidalgo Medina acquired 232 shares of common stock through the vesting of restricted stock units.

Guardant Health Director Tariq Musa reported the acquisition of common stock through RSU vesting and a subsequent sale of a portion of his holdings.

Guardant Health Director Myrtle S. Potter reported the vesting of 68 restricted stock units and the subsequent sale of 26 common shares under a Rule 10b5-1 plan.

Guardant Health's Chief Legal Officer, John G. Saia, vested 1,019 restricted stock units and sold 535 shares to cover tax obligations.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and subsequent share transactions, including tax-related dispositions.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Guardant Health CFO Michael Brian Bell reported the vesting of restricted stock units, leading to an increase in common stock holdings and a sale of shares for tax obligations.

Guardant Health Director Manuel Hidalgo Medina sold 2,165 shares of common stock for a weighted average price of $54.1574 per share.

Guardant Health's Co-Chief Executive Officer, Helmy Eltoukhy, sold 300,000 shares of common stock for approximately $17.8 million through a pre-planned trading arrangement.

Guardant Health Director Meghan V. Joyce sold 100 shares of common stock for $65.84 per share, executed under a pre-arranged Rule 10b5-1 plan.

Guardant Health's Chief Legal Officer, John G. Saia, acquired common stock through RSU vesting and subsequently sold shares to cover tax obligations.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the acquisition of common stock through RSU vesting and the subsequent disposition of shares for tax purposes.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Guardant Health Director Steve Krognes reported the vesting of 155 restricted stock units into common stock on August 31, 2025.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the sale of 2,000 shares of common stock for approximately $123,510.

A director at Guardant Health, Inc. sold 116 shares of common stock for $59.02 per share under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Myrtle S. Potter sold 26 shares of common stock for $59.02 per share under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Manuel Hidalgo Medina converted 232 Restricted Stock Units into common stock, increasing his direct common stock holdings to 3,016 shares.

Guardant Health Director Tariq Musa reported a future acquisition of 250 common shares and 250 restricted stock units, stemming from a pre-existing vesting schedule.

Guardant Health Director Myrtle S. Potter acquired 69 shares of common stock through the vesting of restricted stock units.

Guardant Health Director Meghan V. Joyce reported the acquisition of 67 common shares through the vesting of restricted stock units.

Guardant Health Director Steve Krognes acquired 154 shares of common stock via restricted stock unit vesting.

Guardant Health Director Tariq Musa sold 116 shares of common stock for $48.20 per share on July 17, 2025, as part of a Rule 10b5-1 trading plan.

Myrtle S. Potter, a Director at Guardant Health, Inc., has filed a Form 4 indicating a planned sale of 26 shares of common stock on July 17, 2025, under a Rule 10b5-1 trading plan.